You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 8,563,692

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,563,692

Title:	Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
Abstract:	Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-.alpha.) or interferon beta (IFN-.beta.).
Inventor(s):	Morrison; Sherie L. (Los Angeles, CA), Huang; Tzu-Hsuan (Houston, TX), Xuan; Caiyun (Los Angeles, CA)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	12/985,122
Patent Claims:	1. A composition comprising an interferon attached to a full-length antibody that binds to an antigen expressed in or associated with a cell, wherein the antibody is attached to the interferon by a proteolysis resistant peptide linker, wherein the amino acid sequence of the linker is SGGGGS (SEQ ID NO: 81), and wherein the antibody attached to an interferon, when contacted to a tumor cell, results in the killing or inhibition of growth or proliferation of the tumor cell. 2. The composition of claim 1, wherein said interferon is a type 1 interferon. 3. The composition of claim 1, wherein said interferon is an interferon alpha. 4. The composition of claim 1, wherein said interferon is an interferon beta. 5. The composition of claim 1, wherein said interferon is a type 2 interferon. 6. The composition of claim 1, wherein said linker joins said interferon to the C terminus of the full-length heavy chain of said antibody. 7. The composition of claim 1, wherein the killing or inhibition of growth or proliferation activity of said construct is at least 2-fold greater in vitro against a cell expressing the target marker than the same interferon not attached to a targeting moiety. 8. The composition of claim 1, wherein the antigen is a cancer marker. 9. The composition of claim 1, wherein said antibody specifically binds a marker selected from the group consisting of CD20, HER3, HER2/neu, MUC-1, G250, mesothelin, gp100, tyrosinase, and MAGE. 10. The composition of claim 1, wherein said antibody is an antibody that binds CD20. 11. The composition of claim 1, wherein the antibody is an anti-CD20 antibody, and the interferon is IFN.alpha. or IFN.beta.. 12. The composition of claim 1, wherein said antibody is an antibody that comprises the complementarity determining regions (CDRs) of anti-CD20 rituximab. 13. The composition of claim 12, wherein said antibody is an antibody that comprises the variable regions of anti-CD20 rituximab. 14. The composition of claim 1, wherein the antibody is selected from the group consisting of rituximab, IF5, B1, 1H4, CD19, B4, B43, FVS191, hLL2, LL2, RFB4, M195, HuM195, AT13/5, trastuzumab, 4D5, HuCC49, HUCC39.DELTA.CH2 B72.3, 12C10, IG5, H23, BM-2, BM-7, 12H12, MAM-6, HMFG-1, of C6.5, C6ML3-9, C6 MH3-B1, C6-B1D2, F5, HER3.A5, HER3.F4, HER3.H1, HER3.H3, HER3.E12, HER3.B12, EGFR.E12, EGFR.C10, EGFR.B11, EGFR.E8, HER4.B4, HER4.G4, HER4.F4, HER4.A8, HER4.B6, HER4.D4, HER4.D7, HER4.D11, HER4.D12, HER4.E3, HER4.E7, HER4.F8 and HER4.C7. 15. The composition of claim 14, wherein the antibody is rituximab. 16. A kit comprising the composition of claim 1. 17. An isolated nucleic acid encoding the full-length heavy chain of an antibody attached through the C terminus of said antibody by a linker to an interferon wherein the amino acid sequence of said linker is SGGGGS (SEQ ID NO: 81). 18. A plasmid comprising the isolated nucleic acid of claim 17. 19. An isolated host cell comprising the isolated nucleic acid of claim 17.

Details for Patent 8,563,692

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2027-09-21
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2027-09-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2027-09-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2027-09-21
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2027-09-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.